Abstract: Certain embodiments of the present invention relate to methods and products for use in the determination of treatment of rheumatoid arthritis (RA). Particularly, although not exclusively, embodiments of the present invention relate to predicting the likelihood of a patient suffering from rheumatoid arthritis maintaining remission following cessation of disease-modifying anti-rheumatic drugs (DMARDs). Certain embodiments of the present invention are based on the determination of certain biomarkers of drug-free remission in RA following cessation of DMARD therapy.

Abstract: Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.

Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1);Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.

Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.

Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.

Abstract: An apparatus and method is provided for treating a waste material, particularly an aqueous waste material containing fats, oils and greases (FOG), involving the use of at least two stages in which, in the first stage, the aqueous waste material is subjected to a separation step in which water is removed to leave a partially refined stream containing the FOG followed by a second treatment stage, in which the partially refined FOG stream is further refined by removing more of the water so as to produce a FOG-containing stream that has a low water content which can be used as a fuel. In one embodiment, the refined FOG is used as a fuel for a combustion engine, typically a hydrogen assisted combustion engine for generating electricity. The energy generating plant can be combined with the waste treatment plant or the two can be separated from each other.

Abstract: The isolation and characterization of a metastasis tumor suppressor gene KAI1 is disclosed and diagnostic methods and gene therapy approaches utilizing reagents derived from the nucleotide and deduced amino acid sequences of the KAI1 gene are provided.

Abstract: Use of an aglycosylated antibody having a binding affinity for the CD3 antigen complex is provided for the manufacture of a medicament for treatment of chronic joint inflammation, and more particularly for treating Rheumatoid Arthritis.

Abstract: A method of treating prostate cancer by co-administering a tyrosine kinase inhibitor such as an indolocarbazole and a chemical castration agent is disclosed. A composition containing a tyrosine kinase inhibitor and a chemical castration agent is also disclosed.